Compass Pathways
Compass Pathways Delays Phase 3 Psilocybin Trials, Cuts 30% of Workforce to Conserve Cash
Compass Pathways, psilocybin trials, Phase 3 delays, workforce reduction, cash conservation, psychedelic drug development
Actionable Insights Powered by AI
Compass Pathways, psilocybin trials, Phase 3 delays, workforce reduction, cash conservation, psychedelic drug development